(Q53930312)

22 May 2018

title

Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland. (English)

1 reference

22 May 2018

0 references

1 reference

1 reference

Joumana Hudry

1

1 reference

22 May 2018

Juha O Rinne

2

1 reference

22 May 2018

Tapani Keränen

3

1 reference

22 May 2018

Laurent Eckert

4

1 reference

22 May 2018

John M Cochran

5

1 reference

22 May 2018

language of work or name

English

0 references

publication date

28 March 2006

1 reference

22 May 2018

Annals of Pharmacotherapy

published in

1 reference

22 May 2018

volume

40

1 reference

22 May 2018

issue

4

1 reference

22 May 2018

page(s)

651-657

1 reference

22 May 2018

Direct economic impact of Parkinson's disease: A research survey in the United Kingdom

cites work

1 reference

Clinical practice. Diagnosis and initial management of Parkinson's disease

21 January 2018

1 reference

Motor complications of Parkinson's disease.

21 January 2018

1 reference

Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature

21 January 2018

1 reference

Clinical aspects of Parkinson disease

21 January 2018

1 reference

Impact of the motor complications of Parkinson's disease on the quality of life

21 January 2018

1 reference

The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis

21 January 2018

1 reference

Resource use and costs in a Swedish cohort of patients with Parkinson's disease

21 January 2018

1 reference

Economic burden and quality of life impairment increase with severity of PD.

21 January 2018

1 reference

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

21 January 2018

1 reference

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

21 January 2018

1 reference

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

21 January 2018

1 reference

Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study

21 January 2018

1 reference

The scientific basis for the current treatment of Parkinson's disease

21 January 2018

1 reference

Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease

21 January 2018

1 reference

Rationale for current therapies in Parkinson’s disease

21 January 2018

1 reference

Cost-effectiveness analysis of entacapone in Parkinson's disease: a Markov process analysis

21 January 2018

1 reference

Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States

21 January 2018

1 reference

Psychiatric comorbidities in patients with Parkinson disease and psychosis.

21 January 2018

1 reference

Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.

21 January 2018

1 reference

The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations

21 January 2018

1 reference

A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method.

21 January 2018

1 reference

21 January 2018

1 reference

Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework.

21 January 2018

1 reference

Probabilistic sensitivity analysis for evaluating cost-utility of entacapone for Parkinson's disease

21 January 2018

1 reference

Systematic assessment of decision models in Parkinson's disease.

21 January 2018

1 reference

Patient preferences and utilities for 'off-time' outcomes in the treatment of Parkinson's disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1345/APH.1G454

1 reference

22 May 2018

1 reference

22 May 2018